Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

HYPERTENSION

Renal denervation: one step backwards, three steps forward

Nature Reviews Nephrology volume 14, pages 602–604 (2018)Cite this article

Subjects

Many considered the failure of the SYMPLICITY HTN-3 trial to represent the end of therapeutic renal denervation. However, promising preliminary data from the SPYRAL HTN-OFF MED study and more recently the SPYRAL HTN-ON MED and RADIANCE-HTN SOLO studies support the efficacy of this intervention for blood pressure lowering in patients with hypertension.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Townsend, R. R. et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 390, 2160–2170 (2017).

    Article  Google Scholar 

  2. Kandzari, D. E. et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 391, 2346–2355 (2018).

    Article  Google Scholar 

  3. Azizi, M. et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 391, 2335–2345 (2018).

    Article  Google Scholar 

  4. Krum, H. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373, 1275–1281 (2009).

    Article  Google Scholar 

  5. Esler, M. D. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376, 1903–1909 (2010).

    Article  Google Scholar 

  6. Krum, H. et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383, 622–629 (2014).

    Article  Google Scholar 

  7. Esler, M. D. et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur. Heart J. 35, 1752–1759 (2014).

    Article  Google Scholar 

  8. Mahfoud, F. et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur. Heart J. 35, 2224–2231 (2014).

    Article  Google Scholar 

  9. Bhatt, D. L. et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 370, 1393–1401 (2014).

    Article  CAS  Google Scholar 

  10. Mahfoud, F. et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J. Am. Coll. Cardiol. 66, 1766–1775 (2015).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dobney Hypertension Centre, School of Medicine — Royal Perth Hospital Unit, University of Western Australia, Perth, Western Australia, Australia

    Markus P. Schlaich

  2. Departments of Cardiology and Nephrology, Royal Perth Hospital, Perth, Western Australia, Australia

    Markus P. Schlaich

  3. Neurovascular Hypertension & Kidney Disease Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia

    Markus P. Schlaich

  4. Comprehensive Hypertension Center, Department of Medicine, University of Chicago Medicine, Chicago, IL, USA

    George L. Bakris

Authors
  1. Markus P. Schlaich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George L. Bakris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus P. Schlaich.

Ethics declarations

Competing interests

M.P.S. is supported by a National Health and Medical Research Council (NHMRC) Research Fellowship and has received consulting fees and/or travel and research support from Medtronic, Abbott, Novartis, Servier, Pfizer and Boehringer-Ingelheim. G.L.B. has acted as Consultant for Merck, Relypsa, Vascular Dynamics, Medtronic and Bayer, and has been involved in clinical trials: FIDELIO-Bayer-Principal Investigator, CREDENCE-Steering Committee and CALM-2-Executive Committee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schlaich, M.P., Bakris, G.L. Renal denervation: one step backwards, three steps forward. Nat Rev Nephrol 14, 602–604 (2018). https://doi.org/10.1038/s41581-018-0040-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-018-0040-4

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing